ALVAL Fundamental Analysis - VALBIOTIS SA

Fundamental Rating

ALVAL gets a fundamental rating of 2 out of 10. The analysis compared the fundamentals against 81 industry peers in the Biotechnology industry. ALVAL scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. ALVAL is quite expensive at the moment. It does show a decent growth rate.

Quickly go to:

1. Profitability

1.1 Basic Checks

ALVAL had negative earnings in the past year.

ALVAL had a negative operating cash flow in the past year.

ALVAL had negative earnings in each of the past 5 years.

ALVAL had negative operating cash flow in 4 of the past 5 years.

1.2 Ratios

Looking at the Return On Assets, with a value of -55.55%, ALVAL is doing worse than 66.67% of the companies in the same industry.

ALVAL has a Return On Equity (-92.58%) which is in line with its industry peers.

		Industry Rank	Sector Rank
ROA	-55.55%
ROE	-92.58%
ROIC	N/A

ROA(3y)-39.19%

ROA(5y)-33.23%

ROE(3y)-76.34%

ROE(5y)-68.66%

ROIC(3y)N/A

ROIC(5y)N/A

1.3 Margins

ALVAL does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.

		Industry Rank	Sector Rank
OM	N/A
PM (TTM)	N/A
GM	N/A

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3YN/A

GM growth 5YN/A

More info and screens

ROA

ROE

ROIC

Operating and Profit Margin

Show most profitable peers

2. Health

2.1 Basic Checks

ALVAL does not have a ROIC to compare to the WACC, probably because it is not profitable.

Compared to 1 year ago, ALVAL has about the same amount of shares outstanding.

The number of shares outstanding for ALVAL has been increased compared to 5 years ago.

The debt/assets ratio for ALVAL is higher compared to a year ago.

2.2 Solvency

ALVAL has an Altman-Z score of 0.62. This is a bad value and indicates that ALVAL is not financially healthy and even has some risk of bankruptcy.

ALVAL's Altman-Z score of 0.62 is in line compared to the rest of the industry. ALVAL outperforms 59.26% of its industry peers.

A Debt/Equity ratio of 0.24 indicates that ALVAL is not too dependend on debt financing.

With a Debt to Equity ratio value of 0.24, ALVAL perfoms like the industry average, outperforming 56.79% of the companies in the same industry.

		Industry Rank	Sector Rank
Debt/Equity	0.24
Debt/FCF	N/A
Altman-Z	0.62

ROIC/WACCN/A

WACC6.86%

2.3 Liquidity

A Current Ratio of 3.35 indicates that ALVAL has no problem at all paying its short term obligations.

ALVAL's Current ratio of 3.35 is fine compared to the rest of the industry. ALVAL outperforms 65.43% of its industry peers.

A Quick Ratio of 2.85 indicates that ALVAL has no problem at all paying its short term obligations.

ALVAL has a better Quick ratio (2.85) than 61.73% of its industry peers.

		Industry Rank	Sector Rank
Current Ratio	3.35
Quick Ratio	2.85

More info and screens

WACC

Debt/Equity

How to determine the health of a company

Altman-Z score

Show peers with great health

3. Growth

3.1 Past

ALVAL shows a slight negative growth in Earnings Per Share. In the last year, the EPS has decreased by -7.69%.

The Revenue for ALVAL has decreased by -10.82% in the past year. This is quite bad

ALVAL shows quite a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 13.97% yearly.

EPS 1Y (TTM)-7.69%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%-31.82%

Revenue 1Y (TTM)-10.82%

Revenue growth 3Y-16.26%

Revenue growth 5Y13.97%

Sales Q2Q%842.86%

3.2 Future

The Earnings Per Share is expected to grow by 25.24% on average over the next years. This is a very strong growth

ALVAL is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 343.53% yearly.

EPS Next Y45.28%

EPS Next 2Y25.94%

EPS Next 3Y25.24%

EPS Next 5YN/A

Revenue Next Year375%

Revenue Next 2Y461.25%

Revenue Next 3Y343.53%

Revenue Next 5YN/A

3.3 Evolution

The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.

More info and screens

Find the best growth stocks

Show best growing peers

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for ALVAL. In the last year negative earnings were reported.

Also next year ALVAL is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A

4.2 Price Multiples

		Industry Rank	Sector Rank
P/FCF	N/A
EV/EBITDA	N/A

4.3 Compensation for Growth

ALVAL's earnings are expected to grow with 25.24% in the coming years. This may justify a more expensive valuation.

PEG (NY)N/A

PEG (5Y)N/A

EPS Next 2Y25.94%

EPS Next 3Y25.24%

More info and screens

Show best valued peers

5. Dividend

5.1 Amount

No dividends for ALVAL!.

		Industry Rank	Sector Rank
Dividend Yield	0%

More info and screens

Find the best dividend stocks

Show peers with best dividend

VALBIOTIS SA

EPA:ALVAL (12/31/2025, 7:00:00 PM)

0.694

-0.01 (-0.86%)

Chartmill FA Rating

GICS SectorHealth Care

GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences

GICS IndustryBiotechnology

Earnings (Last)10-27 2025-10-27

Earnings (Next)03-02 2026-03-02/amc

Inst Owners2.4%

Inst Owner ChangeN/A

Ins Owners2.99%

Ins Owner ChangeN/A

Market Cap16.45M

Revenue(TTM)470.00K

Net Income(TTM)-11.11M

Analysts85.45

Price Target2.21 (218.44%)

Short Float %N/A

Short RatioN/A

Dividend

		Industry Rank	Sector Rank
Dividend Yield	0%

Yearly DividendN/A

Dividend Growth(5Y)N/A

DPN/A

Div Incr Years0

Div Non Decr Years0

Ex-DateN/A

Surprises & Revisions

EPS beat(2)N/A

Avg EPS beat(2)N/A

Min EPS beat(2)N/A

Max EPS beat(2)N/A

EPS beat(4)N/A

Avg EPS beat(4)N/A

Min EPS beat(4)N/A

Max EPS beat(4)N/A

EPS beat(8)N/A

Avg EPS beat(8)N/A

EPS beat(12)N/A

Avg EPS beat(12)N/A

EPS beat(16)N/A

Avg EPS beat(16)N/A

Revenue beat(2)N/A

Avg Revenue beat(2)N/A

Min Revenue beat(2)N/A

Max Revenue beat(2)N/A

Revenue beat(4)N/A

Avg Revenue beat(4)N/A

Min Revenue beat(4)N/A

Max Revenue beat(4)N/A

Revenue beat(8)N/A

Avg Revenue beat(8)N/A

Revenue beat(12)N/A

Avg Revenue beat(12)N/A

Revenue beat(16)N/A

Avg Revenue beat(16)N/A

PT rev (1m)0%

PT rev (3m)-34.02%

EPS NQ rev (1m)N/A

EPS NQ rev (3m)N/A

EPS NY rev (1m)-0.88%

EPS NY rev (3m)9.92%

Revenue NQ rev (1m)N/A

Revenue NQ rev (3m)N/A

Revenue NY rev (1m)0%

Revenue NY rev (3m)-50%

Valuation

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A
P/S	35
P/FCF	N/A
P/OCF	N/A
P/B	1.39
P/tB	1.53
EV/EBITDA	N/A

EPS(TTM)-0.7

EYN/A

EPS(NY)-0.3

Fwd EYN/A

FCF(TTM)-0.44

FCFYN/A

OCF(TTM)-0.43

OCFYN/A

SpS0.02

BVpS0.5

TBVpS0.45

PEG (NY)N/A

PEG (5Y)N/A

Graham NumberN/A

Profitability

		Industry Rank	Sector Rank
ROA	-55.55%
ROE	-92.58%
ROCE	N/A
ROIC	N/A
ROICexc	N/A
ROICexgc	N/A
OM	N/A
PM (TTM)	N/A
GM	N/A
FCFM	N/A

ROA(3y)-39.19%

ROA(5y)-33.23%

ROE(3y)-76.34%

ROE(5y)-68.66%

ROIC(3y)N/A

ROIC(5y)N/A

ROICexc(3y)N/A

ROICexc(5y)N/A

ROICexgc(3y)N/A

ROICexgc(5y)N/A

ROCE(3y)N/A

ROCE(5y)N/A

ROICexgc growth 3YN/A

ROICexgc growth 5YN/A

ROICexc growth 3YN/A

ROICexc growth 5YN/A

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3YN/A

GM growth 5YN/A

F-Score3

Asset Turnover0.02

Health

		Industry Rank	Sector Rank
Debt/Equity	0.24
Debt/FCF	N/A
Debt/EBITDA	N/A
Cap/Depr	-250%
Cap/Sales	53.19%
Interest Coverage	N/A
Cash Conversion	N/A
Profit Quality	N/A
Current Ratio	3.35
Quick Ratio	2.85
Altman-Z	0.62

F-Score3

WACC6.86%

ROIC/WACCN/A

Cap/Depr(3y)37.22%

Cap/Depr(5y)37.66%

Cap/Sales(3y)63.51%

Cap/Sales(5y)68.5%

Profit Quality(3y)N/A

Profit Quality(5y)N/A

High Growth Momentum

Growth

EPS 1Y (TTM)-7.69%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%-31.82%

EPS Next Y45.28%

EPS Next 2Y25.94%

EPS Next 3Y25.24%

EPS Next 5YN/A

Revenue 1Y (TTM)-10.82%

Revenue growth 3Y-16.26%

Revenue growth 5Y13.97%

Sales Q2Q%842.86%

Revenue Next Year375%

Revenue Next 2Y461.25%

Revenue Next 3Y343.53%

Revenue Next 5YN/A

EBIT growth 1Y-25.47%

EBIT growth 3YN/A

EBIT growth 5YN/A

EBIT Next Year20.81%

EBIT Next 3Y25.32%

EBIT Next 5Y25.3%

FCF growth 1Y-3.99%

FCF growth 3YN/A

FCF growth 5YN/A

OCF growth 1Y-3.46%

OCF growth 3YN/A

OCF growth 5YN/A

VALBIOTIS SA / ALVAL.PA FAQ

What is the fundamental rating for ALVAL stock?

ChartMill assigns a fundamental rating of 2 / 10 to ALVAL.PA.

Can you provide the valuation status for VALBIOTIS SA?

ChartMill assigns a valuation rating of 1 / 10 to VALBIOTIS SA (ALVAL.PA). This can be considered as Overvalued.

What is the profitability of ALVAL stock?

VALBIOTIS SA (ALVAL.PA) has a profitability rating of 0 / 10.

How financially healthy is VALBIOTIS SA?

The financial health rating of VALBIOTIS SA (ALVAL.PA) is 4 / 10.

Can you provide the expected EPS growth for ALVAL stock?

The Earnings per Share (EPS) of VALBIOTIS SA (ALVAL.PA) is expected to grow by 45.28% in the next year.

VALBIOTIS SA (ALVAL.PA) Stock Fundamental Analysis

1. Profitability

1.1 Basic Checks

1.2 Ratios

1.3 Margins

More info and screens

2. Health

2.1 Basic Checks

2.2 Solvency

2.3 Liquidity

More info and screens

3. Growth

3.1 Past

3.2 Future

3.3 Evolution

More info and screens

4. Valuation

4.1 Price/Earnings Ratio

4.2 Price Multiples

4.3 Compensation for Growth

More info and screens

5. Dividend

5.1 Amount

More info and screens

VALBIOTIS SA / ALVAL.PA FAQ

What is the fundamental rating for ALVAL stock?

Can you provide the valuation status for VALBIOTIS SA?

What is the profitability of ALVAL stock?

How financially healthy is VALBIOTIS SA?

Can you provide the expected EPS growth for ALVAL stock?